Bio-Techne

Bio-Techne Gross Profit/Assets

The Gross Profit to Assets Ratio of Bio-Techne (TECH) as of Nov 16, 2026 is 29.83 %. In the previous year, Gross Profit to Assets Ratio was 30.90 % — a change of -3.46% (lower).

Gross Profit/Assets

29.83 %

YoY

-3.46%

Last updated:

Gross Profit to Assets Ratio of Bio-Techne is 2026 29.83 % . Gross Profit to Assets Ratio of Bio-Techne was 2025 30.90 % . It decreases by -3.46% lower compared to the previous year.

The Bio-Techne Gross Profit/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit/Assets
Date
Gross Profit/Assets
Jan 1, 2019
25.13 USD
Jan 1, 2020
23.83 USD
Jan 1, 2021
27.97 USD
Jan 1, 2022
32.97 USD
Jan 1, 2023
29.17 USD
Jan 1, 2024
28.47 USD
Jan 1, 2025
30.90 USD
Jan 1, 2026
29.83 USD
The Bio-Techne Gross Profit/Assets history
YEARGross Profit/AssetsYoY
29.83 %-3.46%
30.90 %+8.53%
28.47 %-2.42%
29.17 %-11.50%
32.97 %+17.88%
27.97 %+17.35%
23.83 %-5.16%
25.13 %-7.36%
27.12 %+12.73%
24.06 %-19.28%
29.81 %+3.15%
28.90 %-0.87%
29.15 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio-Techne Stock analysis

What does Bio-Techne do? Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently. Bio-Techne is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio-Techne stock

Gross Profit to Assets Ratio of Bio-Techne is 29.83 % in 2026.

Gross Profit to Assets Ratio of Bio-Techne changed from 30.90 % to 29.83 %, representing a -3.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit to Assets Ratio Bio-Techne since 2006 – with annual values, charts, and detailed analysis.

Gross Profit/Assets measures how efficiently a company uses its assets to generate gross profit. Research shows it is a strong predictor of future stock returns.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Profit to Assets Ratio's Bio-Techne with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Profit to Assets Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Profit to Assets Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Bio-Techne

All Key Metrics — Bio-Techne